Gastrointestinal cancers remain among the most lethal malignancies in the world, and a newly published comprehensive review ...
Faeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The ...
The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is one of the most critical and extensively investigated signaling pathways. It is the central regulator of various cellular processes ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, reviews the rationale for capivasertib in hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results